CrownBio & Coronavirus 

Last Updated March 26th, 2020

Back to Main Page

Keeping Your Projects Moving During the COVID-19 Pandemic

Dear Valued Customer,

I am writing to you today to provide an update on how Crown Bioscience is responding to the novel coronavirus outbreak, and to touch upon some of our efforts to ensure our clients critical research programmes can continue to be progressed. 

Our number one priority remains the safety of all of our employees, their families and the safety of our facilities, and I’m pleased to report that no CrownBio staff have currently tested positive for Covid-19. All our facilities remain open and operational while local Pandemic Action Teams have been set up at each site and key on-site precautions implemented and communicated. Our company-wide Business Continuity Plan (BCP) has been enacted and our Pandemic Response Plan has been made available to all staff, and is available to our clients on our dedicated “Be Safe” website, www.crownbio.com/besafe.

The operational impact of the pandemic varies with location. In China, our operations in both Beijing and Taicang are back up and running at full capacity, and our operations teams in China are initiating and scheduling work in a “business as usual” manner. No new cases of Covid-19 infection have been reported in Jiangsu province, home of our Taicang and Suzhou facilities, for over a month.

Our San Diego and Belton, UK sites are operating under “essential business” criteria. At both sites all non-essential staff have already been advised to work from home, and implementing shift patterns for remaining staff has enabled suitable the safety of our staff through social distancing, as well as minimising disruption. At this time, we’re pleased to confirm that all ongoing studies should be completed as scheduled. 

Keeping Your Projects Moving

When it comes to new studies under consideration or future studies planned for the months ahead, we appreciate that these uncertain times make planning difficult for many of our clients, and with this in mind we’re to providing robust options to enable your projects to be progressed. 

Firstly, our China facilities and teams stand ready to help you place your study with confidence. Furthermore, as the majority of models and services offered by CBSD and CBUK are also available through our China operations, for those clients who prefer working directly with our international sites we provide two additional options:

  1. Proxy SD: A well-established and unique internal platform that enables clients in the US and Europe to continue to interface with the local CBUK and CBSD teams on all aspects of the study, including the Study Director and all contractual/logistical components, while in vivo procedures are conducted in China. 
  2. Priority Placement: For those studies that are unique to CBSD or CBUK, or for when local operations are required, we have introduced a priority queuing system. Your study can be booked, “kicked off”, and work on the protocol started, but invoicing and associated study orders are placed on-hold until scheduling can be confirmed.

If either of these options may be of interest to you, or you have any other questions on how we can provide support to your current needs, please just reach out to your Business Development representative. 

Our sincere thanks for your trust and continued understanding at this challenging time. We will of course continue to monitor the situation closely and will provide immediate updated guidance should the situation develop further.

Yours sincerely,

Jean-Pierre Wery
CEO, Crown Bioscience, Inc.

Back to Main Page